Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Terminated2
Active Not Recruiting1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT03375307Phase 2Active Not RecruitingPrimary

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT04902040Phase 1TerminatedPrimary

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT05969860Phase 2Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05248789Phase 2TerminatedPrimary

OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

Showing all 4 trials

Research Network

Activity Timeline